ロタウイルス予防薬の世界市場レポート 2025年

ロタウイルス予防薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.9％で146億3,000万米ドルに成長します。予測期間の成長は、消化器疾患の負担、世界の拡大、ワクチン接種プログラム、ワクチンの信頼性に起因しています。予測期間の主な動向には、次世代ワクチン、混合ワクチン、ワクチンデリバリーの革新、世界の予防接種協力などがあります。

ロタウイルス予防薬市場の成長は、ワクチンコースの増加によってもたらされると予測されます。ワクチンコースは、特定の疾患に対する予防を目的としたワクチンの特定用量から構成され、ロタウイルス感染との戦いにおいて極めて重要な役割を果たします。ワクチンコースの用量は、免疫学的反応の触媒として作用し、ロタウイルスに対する免疫力を著しく高め、病気のリスクを軽減します。これにより、ワクチンの有効性が全体的に高まる。例として、2022年1月に発表された国連国際児童緊急基金（UNICEF）の報告によると、2022年には約571万コースのRV1-5冷凍ロタウイルスワクチンが製造され、2028年には931万コースに急増すると予測されています。さらに、2022年には529万コースのRV5-2凍結乾燥ロタウイルスワクチンが製造され、2028年には613万コースに増加すると予測されています。その結果、ワクチンの入手可能性が高まることがロタウイルス予防薬市場の原動力となると思われます。

ロタウイルス予防薬市場は、機関投資家の資金調達によって大きな成長が見込まれます。機関への資金援助とは、さまざまなプログラム、ニーズ、プロジェクトを支援するための財政的、人的、物的資源の割り当てを意味します。ロタウイルスの罹患率が上昇していることから、政府機関や民間団体からの資金援助が集まっています。この資金援助には、金銭的援助と技術的援助の両方があり、ロタウイルスワクチンと内服薬の開発のさまざまな段階にまたがっています。その一例として、2022年4月、米国の公立研究大学であるインディアナ大学は、ベンチャーキャピタルGIVAX Inc.から120万米ドルの助成金を獲得しました。この助成金は、ロタウイルスとノロウイルスを組み合わせた乳幼児用経口ワクチンの革新的技術の開発を促進することを目的としています。この画期的な技術は、既存のロタウイルスワクチンの範囲を拡大し、幼児に激しい嘔吐や下痢を引き起こす感染力の強いウイルスであるノロウイルスに対する防御を含めるものです。従って、資金源の利用可能性の増大は、ロタウイルス予防薬市場を推進する態勢を整えています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ロタウイルス予防薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のロタウイルス予防薬市場：成長率分析
• 世界のロタウイルス予防薬市場の実績：規模と成長, 2019-2024
• 世界のロタウイルス予防薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界ロタウイルス予防薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のロタウイルス予防薬市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ロタリックス
• ロタバック
• ロタビンM1
• 経口補水液
• その他の治療法
• 世界のロタウイルス予防薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界のロタウイルス予防薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界のロタウイルス予防薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界のロタウイルス予防薬市場、ロタリックスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単回投与
• マルチドーズ
• 世界のロタウイルス予防薬市場、ロータリー式ワクチンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 液体製剤
• フリーズドライ製剤
• 世界のロタウイルス予防薬市場、ロタビン-M1のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 液体製剤
• フリーズドライ製剤
• 世界のロタウイルス予防薬市場経口補水液の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 電解質溶液
• グルコースベースのソリューション
• 世界のロタウイルス予防薬市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 支持療法
• 下痢止め薬

第7章 地域別・国別分析

• 世界のロタウイルス予防薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のロタウイルス予防薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ロタウイルス予防薬市場：競合情勢
• ロタウイルス予防薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Astra Zeneca Pharmaceuticals LP
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Sinovac Biotech Ltd.
• Astellas Pharma Inc.
• CSL Limited
• Bharat Biotech International Limited
• Daiichi Sankyo Co. Ltd.
• Lupin Limited
• Mitsubishi Tanabe Pharma Corporation
• Serum Institute of India Pvt. Ltd.
• Zydus Lifescience Ltd.
• Emergent BioSolutions Inc.
• Hualan Biological Engineering Inc.
• Biocad Biopharmaceutical Co.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ロタウイルス予防薬市場2029：新たな機会を提供する国
• ロタウイルス予防薬市場2029：新たな機会を提供するセグメント
• ロタウイルス予防薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Rotavirus prophylaxis involves the prevention of rotavirus infection through vaccination, aiming to shield infants and young children from this highly contagious illness that triggers inflammation in the stomach and bowels. The primary objective is to provide protection against the infection's severity.

The primary methods employed for rotavirus prophylaxis include the administration of vaccines such as Rotarix, Rotavac, Rotavin-M1, as well as the utilization of oral rehydration fluids, among other interventions. Rotavirus, a viral agent, is responsible for inducing severe stomach and intestinal disorders, often characterized by symptoms like fever, vomiting, and diarrhea. These interventions are deployed through various routes of administration, including oral and parenteral methods, and are readily accessible through outlets such as hospital pharmacies, retail pharmacies, online pharmacy platforms, and others. The intended beneficiaries of these preventive measures encompass hospitals, specialty clinics, home care services, and various other healthcare settings.

The rotavirus prophylaxis market research report is one of a series of new reports from The Business Research Company that provides rotavirus prophylaxis market statistics, including rotavirus prophylaxis industry global market size, regional shares, competitors with a rotavirus prophylaxis market share, detailed rotavirus prophylaxis market segments, market trends and opportunities and any further data you may need to thrive in the rotavirus prophylaxis industry. This rotavirus prophylaxis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rotavirus prophylaxis market size has grown rapidly in recent years. It will grow from $9.05 billion in 2024 to $10.03 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to vaccine access and equity, emerging rotavirus strains, r&d investments, public health preparedness.

The rotavirus prophylaxis market size is expected to see strong growth in the next few years. It will grow to $14.63 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to gastrointestinal disease burden, global expansion, vaccination programs, vaccine confidence. Major trends in the forecast period include next-generation vaccines, combination vaccines, vaccine delivery innovation, global immunization collaboration.

The growth of the rotavirus prophylaxis market is anticipated to be powered by the rising number of vaccine courses. A vaccine course, which consists of specific doses of a vaccine designed to confer protection against a particular disease, plays a pivotal role in the battle against rotavirus infection. The vaccine course dosage acts as a catalyst for the immunological response, significantly enhancing immunity against rotavirus and reducing the risk of illness. This leads to an overall increase in vaccine efficacy. As an illustration, a report by the United Nations International Children's Emergency Fund (UNICEF) published in January 2022 revealed that approximately 5.71 million courses of RV1-5 frozen rotavirus vaccine were manufactured in 2022, with a projected surge to 9.31 million courses by 2028. Furthermore, 5.29 million courses of RV5-2 lyophilized rotavirus vaccines were produced in 2022, with an expected rise to 6.13 million courses by 2028. Consequently, the growing availability of vaccines will be a driving force behind the rotavirus prophylaxis market.

The rotavirus prophylaxis market is expected to experience significant growth fueled by institutional funding. Institutional funding entails the allocation of financial, human, or material resources to support various programs, needs, or projects. The escalating incidence of rotavirus cases has attracted funding from government bodies and private organizations. This financial support encompasses both monetary and technical assistance, spanning different stages of rotavirus vaccine and oral medication development. To exemplify, in April 2022, Indiana University, a public research university based in the United States, secured a $1.2 million grant from the venture capital firm GIVAX Inc. The grant aims to facilitate the development of innovative technology for a combined oral rotavirus-norovirus vaccine for infants. This groundbreaking technology expands the scope of the existing rotavirus vaccine to include protection against norovirus, a highly contagious virus responsible for severe vomiting and diarrhea in young children. Therefore, the increased availability of funding sources is poised to propel the rotavirus prophylaxis market.

Prominent companies operating in the rotavirus prophylaxis market are actively engaged in vaccine development to meet the evolving demands of consumers. The process of vaccine approvals involves a rigorous and multi-stage development and testing procedure. These approvals are essential in ensuring the safety and effectiveness of vaccines for preventing this viral disease, especially in infants and young children. For instance, in November 2022, GlaxoSmithKline PLC, a U.K.-based pharmaceutical and biotechnology company, announced the approval by the Food and Drug Administration (FDA) of an oral-dosing applicator-only presentation (liquid formulation) of ROTARIX (Rotavirus Vaccine, Live and Oral). This vaccine prevents rotavirus gastroenteritis in infants, caused by G1 and non-G1 types (G3, G4, and G9). The novel oral-dosing applicator-only presentation is entirely liquid and should not be reconstituted before use. Both ROTARIX lyophilized and liquid formulations are administered orally in a two-dose series, containing the same live, human-attenuated rotavirus strain and manufactured using similar methods.

In August 2022, Aspen Pharmacare Holdings Limited (APN), a South Africa-based pharmaceutical company, entered into a strategic collaboration with Serum Institute of India Pvt. Ltd. The partnership with the Serum Institute of India (SII) aimed to manufacture and distribute four Aspen-branded vaccines in Africa. This collaboration sought to bolster Africa's health manufacturing capacity and provide affordable vaccine access to the African population. Serum Institute of India Pvt. Ltd. is a vaccine manufacturer based in India, including vaccines for rotavirus.

Major companies operating in the rotavirus prophylaxis market are Pfizer Inc., Johnson & Johnson, Merck & Co., Novartis AG, Sanofi SA, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Sinovac Biotech Ltd., Astellas Pharma Inc., CSL Limited, Bharat Biotech International Limited, Daiichi Sankyo Co. Ltd., Lupin Limited, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Pvt. Ltd., Zydus Lifescience Ltd., Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Biocad Biopharmaceutical Co., Bharat Serums and Vaccines Limited, Biological E Limited, PT Bio Farma, Panacea Biotec Ltd., Shanghai Institute of Biological Products (SIBP).

North America was the largest region in the rotavirus prophylaxis market in 2024. The regions covered in rotavirus prophylaxis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rotavirus prophylaxis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rotavirus prophylaxis market consists of revenues earned by entities by providing services such as vaccination, clinical management, awareness programs and diagnosis. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rotavirus Prophylaxis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rotavirus prophylaxis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rotavirus prophylaxis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rotavirus prophylaxis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Rotarix; Rotavac; Rotavin-M1; Oral Rehydration Fluid; Other Treatments
• 2) By Route of Administration: Oral; Parenteral; Other Route of Administrations
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Rotarix: Single Dose; Multi-Dose
• 2) By Rotavac: Liquid Formulation; Freeze-Dried Formulation
• 3) By Rotavin-M1: Liquid Formulation; Freeze-Dried Formulation
• 4) By Oral Rehydration Fluid: Electrolyte Solutions; Glucose-Based Solutions
• 5) By Other Treatments: Supportive Care; Antidiarrheal Medications
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co.; Novartis AG; Sanofi SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rotavirus Prophylaxis Market Characteristics

3. Rotavirus Prophylaxis Market Trends And Strategies

4. Rotavirus Prophylaxis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Rotavirus Prophylaxis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Rotavirus Prophylaxis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Rotavirus Prophylaxis Market Growth Rate Analysis
• 5.4. Global Rotavirus Prophylaxis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Rotavirus Prophylaxis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Rotavirus Prophylaxis Total Addressable Market (TAM)

6. Rotavirus Prophylaxis Market Segmentation

• 6.1. Global Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rotarix
• Rotavac
• Rotavin-M1
• Oral Rehydration Fluid
• Other Treatments
• 6.2. Global Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route of Administrations
• 6.3. Global Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.4. Global Rotavirus Prophylaxis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.5. Global Rotavirus Prophylaxis Market, Sub-Segmentation Of Rotarix, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single Dose
• Multi-Dose
• 6.6. Global Rotavirus Prophylaxis Market, Sub-Segmentation Of Rotavac, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liquid Formulation
• Freeze-Dried Formulation
• 6.7. Global Rotavirus Prophylaxis Market, Sub-Segmentation Of Rotavin-M1, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liquid Formulation
• Freeze-Dried Formulation
• 6.8. Global Rotavirus Prophylaxis Market, Sub-Segmentation Of Oral Rehydration Fluid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Electrolyte Solutions
• Glucose-Based Solutions
• 6.9. Global Rotavirus Prophylaxis Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Supportive Care
• Antidiarrheal Medications

7. Rotavirus Prophylaxis Market Regional And Country Analysis

• 7.1. Global Rotavirus Prophylaxis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Rotavirus Prophylaxis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rotavirus Prophylaxis Market

• 8.1. Asia-Pacific Rotavirus Prophylaxis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rotavirus Prophylaxis Market

• 9.1. China Rotavirus Prophylaxis Market Overview
• 9.2. China Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rotavirus Prophylaxis Market

• 10.1. India Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rotavirus Prophylaxis Market

• 11.1. Japan Rotavirus Prophylaxis Market Overview
• 11.2. Japan Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rotavirus Prophylaxis Market

• 12.1. Australia Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rotavirus Prophylaxis Market

• 13.1. Indonesia Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rotavirus Prophylaxis Market

• 14.1. South Korea Rotavirus Prophylaxis Market Overview
• 14.2. South Korea Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rotavirus Prophylaxis Market

• 15.1. Western Europe Rotavirus Prophylaxis Market Overview
• 15.2. Western Europe Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rotavirus Prophylaxis Market

• 16.1. UK Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rotavirus Prophylaxis Market

• 17.1. Germany Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rotavirus Prophylaxis Market

• 18.1. France Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rotavirus Prophylaxis Market

• 19.1. Italy Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rotavirus Prophylaxis Market

• 20.1. Spain Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rotavirus Prophylaxis Market

• 21.1. Eastern Europe Rotavirus Prophylaxis Market Overview
• 21.2. Eastern Europe Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rotavirus Prophylaxis Market

• 22.1. Russia Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rotavirus Prophylaxis Market

• 23.1. North America Rotavirus Prophylaxis Market Overview
• 23.2. North America Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rotavirus Prophylaxis Market

• 24.1. USA Rotavirus Prophylaxis Market Overview
• 24.2. USA Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rotavirus Prophylaxis Market

• 25.1. Canada Rotavirus Prophylaxis Market Overview
• 25.2. Canada Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rotavirus Prophylaxis Market

• 26.1. South America Rotavirus Prophylaxis Market Overview
• 26.2. South America Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rotavirus Prophylaxis Market

• 27.1. Brazil Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rotavirus Prophylaxis Market

• 28.1. Middle East Rotavirus Prophylaxis Market Overview
• 28.2. Middle East Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rotavirus Prophylaxis Market

• 29.1. Africa Rotavirus Prophylaxis Market Overview
• 29.2. Africa Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rotavirus Prophylaxis Market Competitive Landscape And Company Profiles

• 30.1. Rotavirus Prophylaxis Market Competitive Landscape
• 30.2. Rotavirus Prophylaxis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Rotavirus Prophylaxis Market Other Major And Innovative Companies

• 31.1. Astra Zeneca Pharmaceuticals LP
• 31.2. GlaxoSmithKline plc
• 31.3. Takeda Pharmaceutical Company Limited
• 31.4. Sinovac Biotech Ltd.
• 31.5. Astellas Pharma Inc.
• 31.6. CSL Limited
• 31.7. Bharat Biotech International Limited
• 31.8. Daiichi Sankyo Co. Ltd.
• 31.9. Lupin Limited
• 31.10. Mitsubishi Tanabe Pharma Corporation
• 31.11. Serum Institute of India Pvt. Ltd.
• 31.12. Zydus Lifescience Ltd.
• 31.13. Emergent BioSolutions Inc.
• 31.14. Hualan Biological Engineering Inc.
• 31.15. Biocad Biopharmaceutical Co.

32. Global Rotavirus Prophylaxis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rotavirus Prophylaxis Market

34. Recent Developments In The Rotavirus Prophylaxis Market

35. Rotavirus Prophylaxis Market High Potential Countries, Segments and Strategies

• 35.1 Rotavirus Prophylaxis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Rotavirus Prophylaxis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Rotavirus Prophylaxis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer